CTOs on the Move


 
Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.   Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly ...
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion
  • www.aptuit.com
  • 2 Greenwich Office Park
    Greenwich, CT USA 06831
  • Phone: 855.506.6360

Executives

Name Title Contact Details

Similar Companies

Therigy

Therigy® is a patient-focused specialty therapy management company. As an industry pioneer, Therigy continues to lead the specialty pharmacy market as the top choice in technology and consulting solutions—with the best possible outcomes for patients in mind.

Integrum

Integrum has since its foundation been helping amputees towards an improved quality of life. We specialize in the osseointegration method.

Vinta Bio

VintaBio is a life sciences company that specializes in customized process development, GMP manufacturing, and quality control services for cell and gene therapies.

Tracon Pharmaceuticals

Tracon Pharmaceuticals, is a biopharmaceutical company that licenses, develops, and commercializes targeted therapies for cancer and age-related macular degeneration. The current pipeline takes advantage of established platform technologies to block novel pathways implicated in cancer growth and angiogenesis.

Apexigen, Inc

Apexigen, Inc. is a privately held biopharmaceutical company discovering and developing innovative antibody therapeutics for the treatment of life-threatening and difficult-to-treat diseases. Using its proprietary antibody technology platform, Apexigen has discovered a pipeline of product candidates, which are currently at varying stages of development. The lead product candidate, APX005M, is a novel immuno-oncology antibody that stimulates and enhances an immune response against cancer. Apexigen is developing other product candidates in partnership with four leading biopharmaceutical companies in China. In addition, Apexigen has formed strategic partnerships with multi-national pharmaceutical companies, including Janssen Biotech, Alcon Laboratories and Toray Industries to discover first-in-class antibody lead candidates for the partners' programs.